Alnylam Pharmaceuticals Inc (ALNY) 293.58 USD (-0.01%)

Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on developing RNA interference-based therapies.

biotechnology

Price history of Alnylam Pharmaceuticals Inc

Performance & Momentum

6 Months 34.14 %

1 Year 0.65 %

3 Years 52.07 %

5 Years 109.50 %

Momentum

Unlock this indicator

Strategic Analysis

Alnylam Pharmaceuticals Inc • 2026

Alnylam Pharmaceuticals is a leading player in biotechnology based on RNA interference, with an approach focused on innovative therapies addressing serious diseases that are often underserved by conventional treatments. Its positioning is built on differentiated scientific expertise and on a niche with high technological barriers, where intellectual property and the ability to turn research into commercial products are key.

Strengths

Recognized leader in RNA interference, with a breakthrough technology that is difficult to replicate
Exposure to a healthcare segment with significant unmet medical needs, offering substantial value-creation potential
Strong long-term stock market track record, reflecting market confidence in the platform and pipeline

Weaknesses

High dependence on the clinical, regulatory, and commercial success of programs that remain execution-sensitive
A naturally volatile biotech profile, with sharp correction phases when expectations deteriorate

Momentum

Momentum remains broadly favorable despite a recent pullback, suggesting a pause after strong appreciation across multiple time horizons. The underlying trend remains constructive for a scientific growth story, but the implied valuation and sensitivity to clinical news warrant a cautious stance in the near term.

Analysis performed 1 month ago